Clinical Trial COGACNS1022


ACNS1022 - A Phase II Randomized Trial of Lenalidomide (NSC# 703813, InD# 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Principal Investigator(s)

Adam Esbenshade


  • Protocol No. COGACNS1022
  • Open Date: 06/09/2012
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To determine the objective response rate of children with recurrent, refractory or progressive juvenile pilocytic astrocytomas and optic pathway gliomas who are treated with Regimen A low-dose (20 mg/m2/dose) or Regimen B high-dose (115 mg/m2/dose) lenalidomide.
  • Disease Sites: Neuro-Oncology; Pediatric Solid Tumors
  • Therapies: None Specified
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01553149
  • Secondary Protocol No: ACNS1022



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.